Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

SFDA approves China Medical PCR KRAS assay

The China's State Food and Drug Administration (SFDA) has approved China Medical Technologies' real-time PCR-based V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) assay as a companion diagnostic test for the use of a targeted drug to treat colorectal cancer patients.

The PCR KRAS assay detects specific mutations in the KRAS gene using a real-time PCR analyzer and predicts which colorectal cancer patients are likely to respond to and benefit from the targeted drug.

The company’s other products include Fish Her-2 kit for breast cancer targeted drug and stomach cancer targeted drug, Fish BCR/ABL kit for leukemia targeted drug and Fish EGFR kit and PCR EGFR assay for non-small cell lung cancer targeted drug.